Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
OPK-88006 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
OPK-88006: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
OPGx-002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
OPGx-002: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Autologous Nucleus Pulposus Cells(ASTEROGENE Biomedical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Autologous Nucleus Pulposus Cells(ASTEROGENE Biomedical): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing dea
9 min read
Sellekstaurin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Sellekstaurin: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
StemVacs-V iPSC derived dendritic cell immunotherapy (Therapeutic Solutions International) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
StemVacs-V iPSC derived dendritic cell immunotherapy (Therapeutic Solutions International): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clini
9 min read
NY-ESO-1TCR/dnTGFBRII Engineered T Cells (The University of Chicago) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
NY-ESO-1TCR/dnTGFBRII Engineered T Cells (The University of Chicago): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, l
9 min read
BCMA/GPRC5D CAR-T cells(Essen Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
BCMA/GPRC5D CAR-T cells(Essen Biotech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market positio
9 min read
Donor-derived Anti-leukemia Cytotoxic T Lymphocytes(Fondazione IRCCS Policlinico San Matteo) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Donor-derived Anti-leukemia Cytotoxic T Lymphocytes(Fondazione IRCCS Policlinico San Matteo): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers cli
9 min read
PH020 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
PH020: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
S-247240 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
S-247240: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
JS-006 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
JS-006: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
[68Ga]Ga-DPI-4452 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
[68Ga]Ga-DPI-4452: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.